PubMed Health⌕ Search

Biomedical subjects

E Skala

Publications and source records attributed to E Skala.

At least 19 recordsLinked to original sources
PubMed2004

[Clinical study of Hodgkin's disease after 25 years].

BACKGROUND: On the 25th anniversary of the unified protocol of 1978, the authors report the results of the first clinical study in the Czech Republic performed in patients with Hodgkin's lymphoma. 290 patients were treated with both chemotherapy (Cyklophosphamide, Natulan, Prednison, Vinblastin) and radiotherapy according to this widely used protocol. The dosage of cytotoxic therapy was reduced based on age, in patients over 50 years of age. METHODS AND RESULTS: In the year 2003, the survival rate was 77.3% (194/290 patients) and of these, 85% (165/194 patients) have lived more than 10 years with complete remission. Of the 194 surviving patients, 24 were successfully treated for relapses. Of the 66 (22.8%) patients that died, the cause of death in 33 patients was Hodgkin's lymphoma. 33 women of the studied group gave birth to 43 children. In one case, phocomelia was diagnosed post-partum. In this instance, no causal relationship to the cytotoxic treatment (which had been given three years before the birth) could be established. The second child of the same mother was born healthy. In one case, a possible genetic relationship was noted--both the father and the daughter suffered from Hodgkin lymphoma and the granddaughter from non-Hodgkin lymphoma. CONCLUSIONS: The success of this treatment depends on complex diagnostic procedures, and on an experienced team of physicians.

Adult↗
PubMed1995

[The significance of mediastinal involvement and other risk factors for survival in patients with Hodgkin's disease].

The impact of prognostic factors for survival was analyzed in a group of 337 patients with Hodgkin's disease. The analysis of survival of patients comprised a total of 13 indicators: histological types LP, NS, MC, LD, clinical stages I, II, III, IV, E lesions, symptomatology A, B, size of the mediastinal tumour (index), age at onset of disease and sex. Cumulative survival of 5, 10, and 20 years in the whole group is 83%, 80% and 72% resp. A first complete remission was achieved by 284 patients, cumulative survival without the disease is 79% after 5 and 73% after 10 years since completion of primary treatment. A significantly adverse effect on the prognosis of survival is exerted by symptomatology B, a large mediastinal tumour, advanced age, clinical stage IV and III. Most important are the first two factors mentioned. An adverse prognostic factor for survival without disease is male sex. The therapeutic protocol was repeatedly modified in the course of 25 years with regard to prognostic patient groups.

Adult↗
PubMed1995

[Pulmonary complications and their prevention in the treatment of Hodgkin's disease].

Pulmonary ventilation was monitored in a group of 102 patients with Hodgkin's disease. In the initial finding a tendency of a restrictive disorder is apparent (43% of the patients) with the increasing size of the mediastinal tumour (79% mediastinal patients with a bulky finding in 40%), without statistical significance. After treatment a restrictive disorder was recorded in 35% of the patients with a normal initial finding and conversely normalization of results occurred in 12% patients with a pathological result of the spirometric examination. After a one-year interval the finding deteriorated in 12 % of the patients without post-treatment disorders of pulmonary ventilation and in 15% the assessed disorder receded. Statistical analysis did not reveal a significant relationship between the results of spirometry and bleomycin treatment. 77 patients were examined after an interval of 2, 3, 4 and more years following termination of primary treatment without a significant correlation of the development of the a restrictive disorder and bleomycin administration. Pulmonary ventilation after treatment was examined in a total of 228 patients with the finding of restrictive changes in 94 (41%). Pulmonary fibrosis was diagnosed in 21 patients (9%) with a rising incidence two years after terminated treatment.

Adult↗
PubMed1995

[Relapse in Hodgkin's disease. Incidence of relapse in a group of 374 patients from 1 June 1968 to 31 March 1995].

From a group of 366 patients with complete data complete remission was achieved by 290. Fifty-five patients relapsed, 39 men and 16 women, mostly with an initial finding of advanced disease (KS III + IV 64%), with affection of the mediastinum (73%) aged under 40 years. 42% of the relapses were detected within one year after termination of primary treatment and 33% during the subsequent 2 years, the longest interval before a relapse being 20 years. During primary treatment in 63% of the patients chemotherapy was reduced to 75-25% of the total dose of cytostatics with protraction of the interval between cycles in 58% and radiotherapy in another 34% of the patients. 76% of the patients with a first relapse achieved a second complete remission and 29 of them survive without signs of the disease, 12 died from generalized lymphoma. Sixteen patients developed repeated relapses (nine two relapses, four three relapses, another two four relapses and one patient five relapses). After treatment of the relapse a total of 22 patients died, incl. 19 who died from Hodgkin's disease, two from secondary carcinoma and one from myocardial infarction. The longest survival period after treatment of a relapse was 26 years.

Adult↗
PubMed1994

[Children of parents treated for Hodgkin's disease using irradiation and chemotherapy].

The authors describe data on the course of pregnancy, delivery and subsequent development of 20 children born to parents treated for Hodgkin's disease. Thirteen women in the clinical stage II and III were delivered of 16 infants (10 daughters and 6 sons) and three men (II A and III A) had four daughters. The parents were in one case treated by irradiation only, twice by chemotherapy only and thirteen times by a combination of irradiation and chemotherapy (COPP/ABVD). The gestation period, parameters of the infants at delivery and the subsequent physical and mental development are normal. In one instance (a girl, now ten and a half years old) the child was born with malformations of the extremities; according to the geneticist this is not related to the previous treatment of the mother. The second child (a son) of this mother is normal. The authors are of the opinion and apply it in the therapeutic protocol in patients of fertile age and do not irradiate nodes in the pelvic region. In treated patients they allow pregnancy only after three or preferably five years following terminated treatment. Survival of patients in the whole group (269 subjects) regardless of age and clinical stage is 75%. The authors are processing a data base of Hodgkin patients since 1968.

Adult↗
PubMed1983

[Flavellagic acid influence on blood coagulation and hemostasis disturbed by whole body irradiation].

By experimentations in vitro with human blood, we found out that an addition of flavellagic acid influences the initial stage of the coagulation system by activating the XIIth coagulation factor. So there is another substance besides the ellagic acid that activates in solution the XIIth coagulation factor. Our experimentations on sound rats showed that an intravenous administration of flavellagic acid in a dose of 0.7 mg/kg body weight has a short-term hemostatic action and that the r and k values and the m epsilon value in the thrombelastogram are increased. There was a similar effect in rats receiving an intravenous injection of flavellagic acid on the twelfth day after a whole-body irradiation with 8.0 Gy.

Animals↗